{"id":"triple-oral-lipid-lowering-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Triple oral lipid lowering treatment combines three distinct oral agents that work through different mechanisms—typically including a statin (HMG-CoA reductase inhibitor), an ezetimibe (cholesterol absorption inhibitor), and a PCSK9 inhibitor or bempedoic acid—to achieve synergistic reductions in LDL cholesterol, triglycerides, and other atherogenic lipids. This multi-target approach aims to provide superior lipid control compared to dual or monotherapy regimens.","oneSentence":"A combination therapy that simultaneously targets multiple pathways involved in lipid metabolism to reduce cholesterol and triglycerides.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:54:31.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia and dyslipidemia management"},{"name":"Cardiovascular risk reduction in patients with inadequate response to dual therapy"}]},"trialDetails":[{"nctId":"NCT07440381","phase":"PHASE3","title":"triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE","status":"NOT_YET_RECRUITING","sponsor":"Heart Care Foundation","startDate":"2026-09","conditions":"Acute Coronary Syndromes, Secondary Prevention, Lipids","enrollment":600},{"nctId":"NCT07255820","phase":"PHASE4","title":"Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol","status":"NOT_YET_RECRUITING","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Triple oral lipid lowering treatment","genericName":"Triple oral lipid lowering treatment","companyName":"Heart Care Foundation","companyId":"heart-care-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination therapy that simultaneously targets multiple pathways involved in lipid metabolism to reduce cholesterol and triglycerides. Used for Hyperlipidemia and dyslipidemia management, Cardiovascular risk reduction in patients with inadequate response to dual therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}